Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Wells Fargo & Co — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Wells Fargo & Co trades at $80.9 (market cap $242.35B). The key difference: Wells Fargo & Co is far larger — about 249.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Wells Fargo & Co pays a 2.48% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Wells Fargo & Co for 88 Days on average.
| MRVI | WFC | |
|---|---|---|
Market Cap | $972.90M | $242.35B |
Volume | 4,325,710 | 25,561,701 |
Sector | Health | Financials |
52-Week High | $9.00 | $96.40 |
52-Week Low | $2.83 | $73.42 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $1.08B | $424.64B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Wells Fargo (WFC) trades at $80.91, down 2.88% on the day, amid mixed technical signals with a bullish overall trend but bearish moving averages. The bank shows strong fundamentals with a P/E of 11.74, net income margin of 25.97%, and consistent earnings beats in recent quarters. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and renewed technology agreements supporting mortgage servicing.
The stock presents a value opportunity with a consensus price target of $98.75, implying 22% upside, supported by analyst bullishness (46.66% buy ratings). Key risks include volatile cash flows, with operating cash flow negative in 2025, and sensitivity to interest rate changes as highlighted by recent Fed hikes (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
